Infliximab is an approved monoclonal antibody for autoimmune diseases that blocks the interconnection of tumor necrosis factor-alpha (TNFα) with its specific receptors and impede a lot of TNFα-related secondary reactions, including inflammation and leukocytes extravasation.7-10 Infliximab specifically blocks TNFα and does not have any impact on TNFβ.11 This evidence concerns the gene TNF and autoimmune disease.